Safety and efficiency of Wharton's Jelly-derived mesenchymal stem cell administration in patients with traumatic brain injury: First results of a phase I study

Basit Öğe Kaydı
dc.authorscopusidErdal Karaöz / 7003448087
dc.authorwosidErdal Karaöz / IXE-6677-2023
dc.contributor.authorKabataş, Serdar
dc.contributor.authorCivelek, Erdinç
dc.contributor.authorBoyalı, Osman
dc.contributor.authorSezen, Gülseli Berivan
dc.contributor.authorÖzdemir, Ömer
dc.contributor.authorBahar-Özdemir, Yeliz
dc.contributor.authorKaplan, Necati
dc.contributor.authorSavrunlu, Eyüp Can
dc.contributor.authorKaraöz, Erdal
dc.date.accessioned2025-04-18T10:24:14Z
dc.date.available2025-04-18T10:24:14Z
dc.date.issued2024
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü
dc.description.abstractBACKGROUND Traumatic brain injury (TBI) is characterized by a disruption in the normal function of the brain due to an injury following a trauma, which can potentially cause severe physical, cognitive, and emotional impairment. Stem cell transplantation has evolved as a novel treatment modality in the management of TBI, as it has the potential to arrest the degeneration and promote regeneration of new cells in the brain. Wharton's Jelly-derived mesenchymal stem cells (WJ-MSCs) have recently shown beneficial effects in the functional recovery of neurological deficits. AIM To evaluate the safety and efficiency of MSC therapy in TBI. METHODS We present 6 patients, 4 male and 2 female aged between 21 and 27 years who suffered a TBI. These 6 patients underwent 6 doses of intrathecal, intramuscular (i.m.) and intravenous transplantation of WJ-MSCs at a target dose of 1 x 10(6)/kg for each application route. Spasticity was assessed using the Modified Ashworth scale (MAS), motor function according to the Medical Research Council Muscle Strength Scale, quality of life was assessed by the Functional Independence Measure (FIM) scale and Karnofsky Performance Status scale. RESULTS Our patients showed only early, transient complications, such as subfebrile fever, mild headache, and muscle pain due to i.m. injection, which resolved within 24 h. During the one year follow-up, no other safety issues or adverse events were reported. These 6 patients showed improvements in their cognitive abilities, muscle spasticity, muscle strength, performance scores and fine motor skills when compared before and after the intervention. MAS values, which we used to assess spasticity, were observed to statistically significantly decrease for both left and right sides (P < 0.001). The FIM scale includes both motor scores (P < 0.05) and cognitive scores (P < 0.001) and showed a significant increase in pretest posttest analyses. The difference observed in the participants' Karnofsky Performance Scale values pre and post the intervention was statistically significant (P < 0.001). CONCLUSION This study showed that cell transplantation has a safe, effective and promising future in the management of TBI.
dc.identifier.citationKabatas, S., Civelek, E., Boyalı, O., Sezen, G. B., Ozdemir, O., Bahar-Ozdemir, Y., ... & Karaöz, E. (2024). Safety and efficiency of Wharton’s Jelly-derived mesenchymal stem cell administration in patients with traumatic brain injury: First results of a phase I study. World Journal of Stem Cells, 16(6), 641.
dc.identifier.doi10.4252/wjsc.v16.i6.641
dc.identifier.endpage655
dc.identifier.issn1948-0210
dc.identifier.issue6
dc.identifier.scopus2-s2.0-85196975671
dc.identifier.scopusqualityQ1
dc.identifier.startpage641
dc.identifier.urihttp://dx.doi.org/10.4252/wjsc.v16.i6.641
dc.identifier.urihttps://hdl.handle.net/20.500.12713/7051
dc.identifier.volume16
dc.identifier.wosWOS:001265138300005
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.institutionauthorKaraöz, Erdal
dc.institutionauthoridErdal Karaöz / 0000-0002-9992-833X
dc.language.isoen
dc.publisherBaishideng publishing group
dc.relation.ispartofWorld journal of stem cells
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTraumatic Brain Injury
dc.subjectWharton Jelly
dc.subjectStem Cell Therapy
dc.subjectTransplantation
dc.subjectMesenchymal Stem Cell
dc.titleSafety and efficiency of Wharton's Jelly-derived mesenchymal stem cell administration in patients with traumatic brain injury: First results of a phase I study
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
WJSC-16-641.pdf
Boyut:
894.21 KB
Biçim:
Adobe Portable Document Format
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Bölümü Makale Koleksiyonu